Sample Publications

insights into the evidence we provide our partners

Stem Cell Therapy for Treatment of Osteoarthritis of the Knee


Technology Stem cell therapy
Manufacturer Not applicable
Focus of Report This report is focused on the use of stem cell therapy for the treatment of knee osteoarthritis. It will be used for support of coverage determinations and policy development.
Literature Summary Eleven abstracts were retrieved for this report including prospective uncontrolled studies, a retrospective comparative study, retrospective uncontrolled studies, a registry study, systematic reviews with meta-analyses, and a systematic review.
Regulatory Status Stem cell therapy is a procedure and, therefore, not subject to FDA regulation.
CE Marking/EMA N/A
Payer Coverage Four commercial payers (Aetna, Anthem Blue Cross, Regence Group, and Wellmark BC/BS) have coverage policies related to stem cell therapy for orthopedic indications. There was no National Coverage Determination (NCD) for this technology on the Centers for Medicare & Medicaid Services (CMS) website.
Conclusion Sufficient published evidence to evaluate this technology - conflicting findings presented in abstracts.

Download the report to continue reading...

Get the Full Report